Archive for the ‘Glomerulonephritis’ Category

May 1, 2017

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction

.   .   

In this open label, multicenter study conducted over 1-year follow-up randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m2, to receive standard therapy or rituximab with standard therapy. median baseline serum creatinine level (range) was 1.4 (0.8-2.4) […]

No Comments Posted in Clinical Nephrology, General Nephrology, Glomerulonephritis
February 9, 2017

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

.   .   

This is a multicenter, randomized, controlled trial conducted at 31 French hospital. Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). During the observational phase, remission rates […]

No Comments Posted in Clinical Nephrology, Clinical Trial Results, Glomerulonephritis
November 11, 2016

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases

.   .   

This study measured the urine protein and creatinine centrally in random and 24-hour urine collections at biopsy and longitudinally every 6 months in individuals participating in the Nephrotic Syndrome Study Network (NEPTUNE) cohort with glomerular disease. The results show that in patients with glomerular disease and proteinuria, the urine protein creatinine ratio correlates only moderately with 24-hour urine protein excretion. The results were used to develop estimating equation to derive 24-hour urine protein excretion from random urine protein creatinine ratio values with improved precision. […]

No Comments Posted in Clinical Nephrology, General Nephrology, Glomerulonephritis
August 14, 2016

Lupus nephritis management guidelines compared

.   .   

This review summarizes the 6 difference guidelines for treatment lupus nephritis – the commonalities, differences as well as highlights the recent literature.    

No Comments Posted in Clinical Nephrology, Clinical Practice Guidelines, Glomerulonephritis, Lupus
March 23, 2016

Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis

.   .   

This study randomized patients with LN (class III, IV, or V) to receive induction with low-dose CYC or oral MMF with the exclusion of patients with crescentic LN, a serum creatinine over 265 μmol/l, and neurological or pulmonary lupus were excluded. Maintenance therapy with azathioprine and low-dose corticosteroid was started at end of induction therapy. The complete remission rate was 50% in CYC and […]

No Comments Posted in Acute Kidney Injury, General Nephrology, Glomerulonephritis
September 21, 2015

Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study

.   .   

This retrospective study assessed 1147 patients with IgA nephropathy from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort.  From this group as well a propensity matched cohort, the authors concluded that corticosteroids reduced proteinuria and the rate of renal function decline and increased renal survival even in patients with an eGFR < 50 […]

No Comments Posted in Chronic Kidney Disease, Glomerulonephritis
September 21, 2015

Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015

.   .   

Another great core curriculum that reviews glomerular diseases dependent on complement activation that will benefit both attendings and trainees.

No Comments Posted in AJKD Core Curriculum, Clinical Nephrology, Glomerulonephritis
December 17, 2014

Utility of renal biopsy in the clinical management of renal disease

.   .   

This provocative article describes underutilization of kidney biopsies in the diagnosis and prognosis of renal disease.  The authors state that kidney biopsies can aid in the better management of patients with renal disease at all stages.

No Comments Posted in Clinical Nephrology, General Nephrology, Glomerulonephritis
December 21, 2013

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

.   .   

This randomized trial compared rituximab with cyclophosphamide followed by azathioprine in severe ANCA-associated vasculitis. This noninferiority trial showed that there was no difference at 18 months for the induction and maintenance of remissions between groups.

Comments Off on Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis Posted in Clinical Nephrology, Clinical Trial Results, Glomerulonephritis, Vasculitis
August 23, 2013

Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear

.   .   

This longer term follow-up of PLEX for the treatment of ANCA-associated vasculitis in patients with severely impaired renal function are disappointing. The data suggest that PLEX does not significantly benefit these patients. Current trials are ongoing as to the role of PLEX in ANCA-associated vasculitis.

Comments Off on Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear Posted in Clinical Trial Results, Glomerulonephritis
August 23, 2013

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

.   .   

This randomized double-blind noninferiority trial compared the 18-month efficacy of rituximab + placebo vs cyclophosphamide + azathioprine for the treatment of ANCA-associated vasculitis. Of the 197 patients enrolled, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. The […]

1 Comment Posted in Clinical Nephrology, General Nephrology, Glomerulonephritis
April 1, 2013

Biomarkers in Nephrology: Core Curriculum 2013

.   .   

This article of the AJKD Core Curriculum, reviews biomarkers of kidney disease in the settings of acute kidney injury, chronic kidney disease,nephrotoxin exposure and glomerulonephritis.

Comments Off on Biomarkers in Nephrology: Core Curriculum 2013 Posted in Acute Kidney Injury, AJKD Core Curriculum, Chronic Kidney Disease, Glomerulonephritis